SCHEMBL13401909

SCHEMBL13401909

O=C(CCCCCNS(=O)(=O)c1ccc(Br)cc1)NCc1ccc(F)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.65
POLB P06746 1/20 0.64
CTDSP1 Q9GZU7 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
PKM P14618 1/20 0.57
TSHR P16473 1/20 0.56
LMNA P02545 2/20 0.56
USP2 O75604 1/20 0.55
HDAC3 O15379 3/20 0.54
HDAC1 Q13547 3/20 0.54
KDM4E B2RXH2 1/20 0.54
F2 P00734 1/20 0.53
TMPRSS6 Q8IU80 1/20 0.53
EGFR P00533 2/20 0.53
ERBB2 P04626 2/20 0.53
HPGD P15428 1/20 0.51
HDAC2 Q92769 1/20 0.51
HDAC8 Q9BY41 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13401888 0.91 POLB (0.70) ALDH1A1POLBCTDSP1TDP1MEN1
SCHEMBL19334535 0.88 ALDH1A1 (0.67) ALDH1A1MEN1KMT2ATSHRLMNA
SCHEMBL19334506 0.84 ALDH1A1 (0.61) ALDH1A1MEN1KMT2ATSHRLMNA
SCHEMBL19334330 0.79 USP2 (0.67) ALDH1A1POLBCTDSP1TDP1MEN1
SCHEMBL13401893 0.79 ALDH1A1 (0.88) ALDH1A1POLBTDP1MEN1KMT2A
SCHEMBL19334408 0.79 KMT2A (0.67) ALDH1A1POLBCTDSP1MEN1KMT2A
SCHEMBL13401889 0.78 KMT2A (0.67) ALDH1A1POLBCTDSP1MEN1KMT2A
SCHEMBL19334534 0.78 ALDH1A1 (0.69) ALDH1A1MEN1KMT2ATSHRLMNA
SCHEMBL17229248 0.77 LMNA (0.56) ALDH1A1POLBCTDSP1TDP1MEN1
SCHEMBL12882346 0.76 LMNA (0.61) ALDH1A1POLBCTDSP1TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9757375-B2 Compounds that inhibit human DNA ligases and methods of treating cancer UNIVERSITY OF MARYLAND, BALTIMORE (US) 2017-09-12 US disclosed
US-8445537-B2 Compounds that inhibit human DNA ligases and methods of treating cancer STC.UNM (US) 2013-05-21 US disclosed
US-20100099683-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099683-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER LIG1, LIG4, LIG3 ALDH1A1 2436/4885POLB 17/4885CTDSP1 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.